Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

NCT02500043 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

507

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Metastatic Gastric Cancer

Interventions

DRUG: TAS-102
DRUG: Placebo

Sponsor

Taiho Oncology, Inc.